journal article·2011-12-02Open access

Protein Degradation and Protection Observed in the Presence of Novel Wound Dressing Components

Laura K.S. Parnell

Abstract

Chronic wounds typically have excessive levels of matrix metalloproteinases (MMPs) and proinflammatory cytokines that impair healing. Reducing these detrimental proteins may be key to healing chronic wounds. Proprietary protease blends were formulated specifically to degrade excessive amounts of proinflammatory factors that could prevent wound healing. Applications of protease-containing wound dressings to acute and chronic wounds have been observed clinically to resolve inflammation and appear to aid healing. The purpose of this study was to test in vitro a deliberate blend of proteases for the ability to deactivate or activate known proteins associated with inflammation or healing. Purified human target proteins were incubated with test and control solutions and samples removed at various time points. Blinded samples were tested using a novel infrared protein multiplex sandwich-ELISA-type array technique. Many proinflammatory proteins such as MMPs, cytokines and chemokines were susceptible to degradation. Many proteins such as growth factors, cytokines and TIMP1 were resistant to degradation. Not all proinflammatory proteins were deactivated. Family protein structure did not appear to affect susceptibility to degradation or deactivation. These results suggest that specific protease containing wound dressings appear to reduce multiple detrimental components which may disrupt their deleterious effects on the wound bed and microenvironment. By improving the wound microenvironment through the use of definitive proteases, these novel wound dressings may help transition wounds into the subsequent phase of healing.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Wound Healing and Treatments · Periodontal Regeneration and Treatments · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Precision Consulting, 6522 Harbor Mist, Missouri City, TX 77459, USA

References (36)

Show source-provided references
1. Formation of scab and the rate of epithelialization of superficial wounds in the skin of the domestic pig10.1038/193293a0 ↗
2. Falanga, V. (2001). Cutaneous Wound Healing, Martin Dunitz Ltd.. [1st ed.].
3. Cohen, I.K., Diegelmann, R.F., and Lindblad, W.J. (1992). Wound Healing-Biochemical and Clinical Aspects, W.B. Saunders Company, Harcourt Brace Jovanovich Inc.. [1st ed.].
4. Cytokines and wound healing: The role of cytokines and anticytokine therapy in the repair response10.1097/01.BCR.0000111766.97335.34 ↗
5. Cohen, I.K., Diegelmann, R.F., and Lindblad, W.J. (1992). Wound Healing-Biochemical and Clinical Aspects, W.B. Saunders Company, Harcourt Brace Jovanovich Inc.. [1st ed.].
6. Cohen, I.K., Diegelmann, R.F., and Lindblad, W.J. (1992). Wound Healing-Biochemical and Clinical Aspects, W.B. Saunders Company, Harcourt Brace Jovanovich Inc.. [1st ed.].
7. Cohen, I.K., Diegelmann, R.F., and Lindblad, W.J. (1992). Wound Healing-Biochemical and Clinical Aspects, W.B. Saunders Company, Harcourt Brace Jovanovich Inc.. [1st ed.].
8. Role of inflammatory mediators in angiogenesis10.2174/1568010053622830 ↗
9. Falanga, V. (2001). Cutaneous Wound Healing, Martin Dunitz Ltd.. [1st ed.].
10. Wound-healing studies in transgenic and knockout mice10.1385/MB:28:2:147 ↗
11. Science, medicine and the future: Healing chronic wounds10.1136/bmj.324.7330.160 ↗
12. Innate immunity in aging: Impact on macrophage function10.1111/j.1474-9728.2004.00102.x ↗
13. Epidermal expression of collagenase delays wound-healing in transgenic mice10.1046/j.1523-1747.1998.00457.x ↗
14. Impaired wound healing in mice with a disrupted plasminogen gene
15. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator10.1073/pnas.93.12.5899 ↗
16. Interactions of cytokines, growth factors, and proteases in acute and chronic wound fluid10.1046/j.1524-475X.1996.40404.x ↗
17. Biochemical analysis of acute and chronic wound environments10.1046/j.1524-475X.1996.40307.x ↗
18. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors10.1046/j.1524-475X.1999.00442.x ↗
19. Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers10.1046/j.1524-475X.1996.40211.x ↗
20. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase10.1074/jbc.270.28.16518 ↗
21. Physiology of the chronic wound10.1016/S0094-1298(20)32468-8 ↗
22. European Wound Management Association (EWMA) (2004). Position Document: Wound Bed Preparation in Practice, MEP Ltd.
23. The diabetic ulcer study group. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic ulcers10.1016/S0741-5214(95)70245-8 ↗
24. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers10.1046/j.1524-475X.2002.10703.x ↗
25. Cohen, I.K., Diegelmann, R.F., and Lindblad, W.J. (1992). Wound Healing-Biochemical and Clinical Aspects, W.B. Saunders Company, Harcourt Brace Jovanovich Inc. [1st ed.].
27. Wound dressing components degrade proteins detrimental to wound healing10.1111/j.1742-481X.2007.00422.x ↗
28. Yosipovitch, G., Greaves, M.W., Fleischer, A.B., and McGlone, F. (2004). Itch Basic Mechanisms and Therapy, Marcel Dekker, Inc.. [1st ed.].10.1201/b14233 ↗
29. Yosipovitch, G., Greaves, M.W., Fleischer, A.B., and McGlone, F. (2004). Itch Basic Mechanisms and Therapy, Marcel Dekker, Inc.. [1st ed.].10.1201/b14233 ↗
30. The ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors10.1046/j.1524-475X.1997.50108.x ↗
31. Contact dermatitis treated with new topical products: A case study
32. Brinton, A.M., and Parnell, L.K.S. (2007, January 17–20). Use of a protease containing antifungal to treat damaged and contaminated perineal skin. Orlando, FL, USA.
33. Preliminary use of a hydrogel containing enzymes in the treatment of stage II and stage III pressure ulcers
34. Nedelec, B., Rachelska, G., Parnell, L.K.S., and LaSalle, L. (2011). Double-blind, randomized, pilot study assessing the resolution of post-burn pruritus. J. Burn Care Res., in press.10.1097/BCR.0b013e318233592e ↗
35. Accuzyme papain-urea debriding ointment: A historical review
36. Enzymatic debriding agents: An evaluation of the medical literature